Clinical Trial ProgressThe DRAGON trial is on track to be completed, potentially leading to a regulatory submission in Japan.
Financial PositionThe company raised $15M in gross proceeds in a registered direct offering and ended the quarter with $157M in cash.
Regulatory DesignationBelite has announced it was granted FDA Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease, for which there are currently no approved treatments.